일 정신병원에 입원한 조현병 환자의 대사지표와 관련된 비정형 항정신병약물 요인

초록

Objectives：Patients with schizophrenia have been reported to be more vulnerable to metabolic diseases than the general population. This study aimed to assess the prevalence of abnormal metabolic parameters and identify the factors of atypical antipsychotic drugs associated with these abnormalities in patients with schizophrenia taking atypical antipsychotic drugs. Methods：A total of 161 inpatients with schizophrenia were recruited at Chuncheon National Hospital for 1 year in 2015. We collected demographic information, medication history, physical measurements, and metabolic parameters(body mass index(BMI), systolic and diastolic blood pressures, and serum total cholesterol and serum triglyceride levels) from the medical records of the patients. We categorized the patients into an abnormal metabolic parameters group and a control group and performed comparative analysis between the groups. Results：Among the 161 inpatients, 56.5% were overweight(BMI≥25kg/m2) and 42.2% had hypertension. The prevalence of hypercholesterolemia(total cholesterol level＞200mg/dL) and hypertriglyceridemia(triglyceride level ＞150mg/dL) was 23.6% and 43.5%, respectively. Being overweight was strongly associated with higher total daily chlorpromazine-equivalent dose but not with age, sex, or antipsychotic polypharmacy. Conclusion：Metabolic abnormalities are highly prevalent among patients with chronic schizophrenia. These results suggest that higher chlorpromazine-equivalent doses are associated with greater weight gain. Clinicians should be aware of the risk of metabolic abnormalities associated with a chlorpromazine-equivalent doses of antipsychotic drugs.

키워드